S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
MarketBeat Week in Review – 4/15 - 4/19
Morning sickness? Prenatal check-ups? What to know about new rights for pregnant workers
Tesla cuts US prices for 3 of its electric vehicle models after a difficult week
A coffee roastery in Finland has launched an AI-generated blend. The results were surprising
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
The House votes for possible TikTok ban in the US, but don't expect the app to go away anytime soon
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
NASDAQ:MYGN

Myriad Genetics (MYGN) Stock Price, News & Analysis

$18.50
-0.01 (-0.05%)
(As of 04/19/2024 ET)
Today's Range
$18.25
$18.69
50-Day Range
$18.50
$23.59
52-Week Range
$13.82
$24.21
Volume
487,827 shs
Average Volume
520,382 shs
Market Capitalization
$1.67 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.17

Myriad Genetics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
25.2% Upside
$23.17 Price Target
Short Interest
Bearish
6.27% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.60
Upright™ Environmental Score
News Sentiment
-0.18mentions of Myriad Genetics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.36) to ($0.09) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.11 out of 5 stars

Medical Sector

329th out of 908 stocks

Diagnostic Substances Industry

6th out of 11 stocks

MYGN stock logo

About Myriad Genetics Stock (NASDAQ:MYGN)

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

MYGN Stock Price History

MYGN Stock News Headlines

The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
Myriad Genetics Inc.
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
MYGN Apr 2024 30.000 call
MYGN Aug 2024 21.000 call
MYGN May 2024 18.000 call
Myriad Genetics: Hold Rating Amidst Growth and Market Uncertainty
Q4 2023 Myriad Genetics Inc Earnings Call
Myriad Genetics Inc. Q4 Earnings Summary
See More Headlines
Receive MYGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Myriad Genetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/21/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Diagnostic substances
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MYGN
CUSIP
62855J10
Employees
2,700
Year Founded
1991

Price Target and Rating

Average Stock Price Target
$23.17
High Stock Price Target
$31.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+25.2%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Net Income
$-263,300,000.00
Pretax Margin
-34.81%

Debt

Sales & Book Value

Annual Sales
$753.20 million
Book Value
$9.53 per share

Miscellaneous

Free Float
88,078,000
Market Cap
$1.67 billion
Optionable
Optionable
Beta
1.95

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

MYGN Stock Analysis - Frequently Asked Questions

Should I buy or sell Myriad Genetics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Myriad Genetics in the last year. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" MYGN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MYGN, but not buy additional shares or sell existing shares.
View MYGN analyst ratings
or view top-rated stocks.

What is Myriad Genetics' stock price target for 2024?

6 brokers have issued 12 month price targets for Myriad Genetics' stock. Their MYGN share price targets range from $14.00 to $31.00. On average, they expect the company's stock price to reach $23.17 in the next year. This suggests a possible upside of 25.2% from the stock's current price.
View analysts price targets for MYGN
or view top-rated stocks among Wall Street analysts.

How have MYGN shares performed in 2024?

Myriad Genetics' stock was trading at $19.14 at the beginning of 2024. Since then, MYGN stock has decreased by 3.3% and is now trading at $18.50.
View the best growth stocks for 2024 here
.

When is Myriad Genetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our MYGN earnings forecast
.

How were Myriad Genetics' earnings last quarter?

Myriad Genetics, Inc. (NASDAQ:MYGN) posted its earnings results on Tuesday, February, 27th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.03. The firm had revenue of $196.60 million for the quarter, compared to the consensus estimate of $194.80 million. Myriad Genetics had a negative net margin of 34.96% and a negative trailing twelve-month return on equity of 8.03%. The company's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.20) EPS.

What guidance has Myriad Genetics issued on next quarter's earnings?

Myriad Genetics updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of 0.000-0.050 for the period, compared to the consensus EPS estimate of -0.010. The company issued revenue guidance of $820.0 million-$840.0 million, compared to the consensus revenue estimate of $819.3 million.

What is Paul Diaz's approval rating as Myriad Genetics' CEO?

12 employees have rated Myriad Genetics Chief Executive Officer Paul Diaz on Glassdoor.com. Paul Diaz has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Myriad Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Myriad Genetics investors own include Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Gilead Sciences (GILD), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AT&T (T), Alibaba Group (BABA) and Kratos Defense & Security Solutions (KTOS).

Who are Myriad Genetics' major shareholders?

Myriad Genetics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.06%) and Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Daniel K Spiegelman, Dennis Langer, Jayne B Hart, Jerry S Lanchbury, Jerry S Lanchbury, Nicole Lambert, Richard Bryan Riggsbee and S Louise Phanstiel.
View institutional ownership trends
.

How do I buy shares of Myriad Genetics?

Shares of MYGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Myriad Genetics have any subsidiaries?
The following companies are subsidiares of Myriad Genetics: Assurex Health Inc., Assurex Health Ltd, Counsyl, Crescendo Bioscience, Crescendo Bioscience LLC, Javelin Pharmaceuticals, Myriad Autoimmune, Myriad Genetic Laboratories Inc., Myriad Genetics Australia PTY LTD, Myriad Genetics B.V., Myriad Genetics Canada Corp, Myriad Genetics Espana SL, Myriad Genetics GK, Myriad Genetics GmbH, Myriad Genetics LTD, Myriad Genetics S.r.l., Myriad Genetics SAS, Myriad GmbH, Myriad International GmbH, Myriad Neuroscience, Myriad Services GmbH, Myriad Women’s Health, Myriad Women’s Health Inc, NaturNorth Technologies, Privatklinik Dr. Robert Schindlbeck, Rules-Based Medicine, and Sividon Diagnostics.
Read More
This page (NASDAQ:MYGN) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners